SGM
EWTX icon

Seven Grand Managers’s Edgewise Therapeutics EWTX Stock Holding History

Seven Grand Managers’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60,000
Closed -$590K – 16
2022
Q3 		$590K Buy
+60,000
New +$606K 1.93% 15

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Seven Grand Managers's EWTX Position: Q4 2022 in Review

Seven Grand Managers sold out of Edgewise Therapeutics (EWTX) in Q4 2022, closing a stake of 60,000 shares — an estimated $590K sold.

Seven Grand Managers first reported a position in EWTX in Q3 2022 and held it in 1 quarter. The position peaked at $590K in Q3 2022. 90 funds tracked by Wall St. Rank hold EWTX as of Q4 2022.

  • Seven Grand Managers reported no remaining Edgewise Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Seven Grand Managers sold 60,000 Edgewise Therapeutics shares in Q4 2022, an estimated $590K.
  • Seven Grand Managers first reported a position in Edgewise Therapeutics in Q3 2022 and held it in 1 quarter.
  • Seven Grand Managers's Edgewise Therapeutics position peaked at $590K in Q3 2022.
  • 90 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2022.

Based on Seven Grand Managers's 13F filing for Q4 2022, filed 14 Feb 2023.